<DOC>
	<DOCNO>NCT00310297</DOCNO>
	<brief_summary>Primary objective : To compare pharmacodynamics insulin glulisine insulin lispro inject subcutaneously three 500 kcal standard meal 12 hour day , obese subject type 2 diabetes . Secondary objective : - To compare pharmacokinetics insulin glulisine insulin lispro obese subject type 2 diabetes , inject subcutaneously three standard meal 12-hour day . - The safety insulin glulisine , relationship pharmacodynamics pharmacokinetics skin thickness C-peptide , non-esterified fatty acid , triglyceride β-hydroxybutyrate level subject also assess .</brief_summary>
	<brief_title>Insulin Glulisine Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus Body mass index ( BMI ) 35 40 kg/m2 HbA1c ≤10 % Plasma Cpeptide level ≥0.1 nmol/L . Female subject either postmenopausal , surgically sterilize , pregnant use approve method contraception . Exclusion criterion : Type 1 diabetes mellitus , define World Health Organization Subjects currently take insulin History hypoglycaemic unawareness Injection site skin thickness &lt; = 8 mm Contraindications The medical history physical examination Laboratory test ( haematology , clinical chemistry , urinalysis dipstick ) Blood pressure pulse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>